198 related articles for article (PubMed ID: 33891268)
21. The European Organisation for Research and Treatment of Cancer Quality of Life Utility-Core 10 Dimensions: Development and Investigation of General Population Utility Norms for Canada, France, Germany, Italy, Poland, and the United Kingdom.
Pilz MJ; Nolte S; Liegl G; King M; Norman R; McTaggart-Cowan H; Bottomley A; Rose M; Kemmler G; Holzner B; Gamper EM;
Value Health; 2023 May; 26(5):760-767. PubMed ID: 36572102
[TBL] [Abstract][Full Text] [Related]
22. Comparing and transforming PROMIS utility values to the EQ-5D.
Hartman JD; Craig BM
Qual Life Res; 2018 Mar; 27(3):725-733. PubMed ID: 29264776
[TBL] [Abstract][Full Text] [Related]
23. Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping.
Yang M; Vioix H; Hook ES; Hatswell AJ; Batteson RL; Gaumond BR; O'Brate A; Popat S; Paik PK
Value Health; 2023 Aug; 26(8):1155-1163. PubMed ID: 36805576
[TBL] [Abstract][Full Text] [Related]
24. German value sets for the EORTC QLU-C10D, a cancer-specific utility instrument based on the EORTC QLQ-C30.
Kemmler G; Gamper E; Nerich V; Norman R; Viney R; Holzner B; King M;
Qual Life Res; 2019 Dec; 28(12):3197-3211. PubMed ID: 31485913
[TBL] [Abstract][Full Text] [Related]
25. Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L.
Lorgelly PK; Doble B; Rowen D; Brazier J;
Qual Life Res; 2017 May; 26(5):1163-1176. PubMed ID: 27830513
[TBL] [Abstract][Full Text] [Related]
26. EORTC QLU-C10D value sets for Austria, Italy, and Poland.
Gamper EM; King MT; Norman R; Efficace F; Cottone F; Holzner B; Kemmler G;
Qual Life Res; 2020 Sep; 29(9):2485-2495. PubMed ID: 32458409
[TBL] [Abstract][Full Text] [Related]
27. U.K. utility weights for the EORTC QLU-C10D.
Norman R; Mercieca-Bebber R; Rowen D; Brazier JE; Cella D; Pickard AS; Street DJ; Viney R; Revicki D; King MT;
Health Econ; 2019 Dec; 28(12):1385-1401. PubMed ID: 31482619
[TBL] [Abstract][Full Text] [Related]
28. Can Mapping Algorithms Based on Raw Scores Overestimate QALYs Gained by Treatment? A Comparison of Mappings Between the Roland-Morris Disability Questionnaire and the EQ-5D-3L Based on Raw and Differenced Score Data.
Madan J; Khan KA; Petrou S; Lamb SE
Pharmacoeconomics; 2017 May; 35(5):549-559. PubMed ID: 28063083
[TBL] [Abstract][Full Text] [Related]
29. The EORTC QLU-C10D discrete choice experiment for cancer patients: a first step towards patient utility weights.
Gamper EM; King MT; Norman R; Loth FLC; Holzner B; Kemmler G;
J Patient Rep Outcomes; 2022 May; 6(1):42. PubMed ID: 35507194
[TBL] [Abstract][Full Text] [Related]
30. Health state utility differed systematically in breast cancer patients between the EORTC QLU-C10D and the PROMIS Preference Score.
Klapproth CP; Fischer F; Rose M; Karsten MM
J Clin Epidemiol; 2022 Dec; 152():101-109. PubMed ID: 36162712
[TBL] [Abstract][Full Text] [Related]
31. Are condition-specific utilities more valid than generic preference-based ones in asthma? Evidence from a study comparing EQ-5D-3L and SF-6D with AQL-5D.
Kontodimopoulos N; Stamatopoulou E; Brinia A; Talias MA; Ferreira LN
Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):667-675. PubMed ID: 30048194
[TBL] [Abstract][Full Text] [Related]
32. The EORTC QLU-C10D: the Hong Kong valuation study.
Xu RH; Wong EL; Luo N; Norman R; Lehmann J; Holzner B; King MT; Kemmler G;
Eur J Health Econ; 2024 Jul; 25(5):889-901. PubMed ID: 37768519
[TBL] [Abstract][Full Text] [Related]
33. Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments.
Yang F; Devlin N; Luo N
Eur J Health Econ; 2019 Feb; 20(1):99-105. PubMed ID: 29948432
[TBL] [Abstract][Full Text] [Related]
34. A comparison of the EQ-5D-3L and ICECAP-O in an older post-acute patient population relative to the general population.
Couzner L; Crotty M; Norman R; Ratcliffe J
Appl Health Econ Health Policy; 2013 Aug; 11(4):415-25. PubMed ID: 23807538
[TBL] [Abstract][Full Text] [Related]
35. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.
Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J
Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351
[TBL] [Abstract][Full Text] [Related]
36. Health-Related Quality of Life Associated with Barrett's Esophagus and Cancer.
Bulamu NB; Chen G; Ratcliffe J; Schloite A; Bright T; Watson DI
World J Surg; 2019 Jun; 43(6):1554-1562. PubMed ID: 30719557
[TBL] [Abstract][Full Text] [Related]
37. Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancer.
Lien K; Tam VC; Ko YJ; Mittmann N; Cheung MC; Chan KK
Curr Oncol; 2015 Dec; 22(6):e443-52. PubMed ID: 26715881
[TBL] [Abstract][Full Text] [Related]
38. Health utility assessments in individuals undergoing diagnostic and surveillance colonoscopy: improved discrimination with a cancer-specific scale.
Bulamu NB; Chen G; McGrane E; Cock C; Young GP; Symonds EL
Cancer Causes Control; 2024 Feb; 35(2):347-357. PubMed ID: 37747615
[TBL] [Abstract][Full Text] [Related]
39. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI
Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
[TBL] [Abstract][Full Text] [Related]
40. Catalog of EQ-5D-3L Health-Related Quality-of-Life Scores for 199 Chronic Conditions and Health Risks in Denmark.
Hvidberg MF; Petersen KD; Davidsen M; Witt Udsen F; Frølich A; Ehlers L; Alava MH
MDM Policy Pract; 2023; 8(1):23814683231159023. PubMed ID: 37056295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
